Skip to content

Dyskeratosis Congenita Autosomal Recessive 6 C4225356

Published: July 22, 2026Updated: August 20, 2026

An inherited disorder causing bone marrow failure and telomere abnormalities. Leads to low blood counts and elevated cancer risk. Care involves monitoring blood counts, managing symptoms, and screening for complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Hematopoietic Stem Cell Transplantation

HSCT remains the primary curative option for bone marrow failure in autosomal recessive dyskeratosis congenita subtype 6. Careful donor selection and modified conditioning regimens improve outcomes in this population.

procedure
3

Multi-Organ Surveillance Protocol

Systematic monitoring of hematologic, pulmonary, hepatic, and oncologic parameters through regular clinical assessments, laboratory studies, and imaging to detect complications early.

monitoring

Additional treatment options

Growth Factor Support

Granulocyte colony-stimulating factor or erythropoiesis-stimulating agents may be administered to support blood cell production in selected patients with cytopenias.

medication

Sun Protection and Skin Care

Strict sun avoidance, protective clothing, and broad-spectrum sunscreen reduce risk of skin complications and potential malignant transformation in sun-exposed areas.

lifestyle

Nutritional Support

Comprehensive nutritional assessment and supplementation addressing specific deficiencies common in dyskeratosis congenita, including iron, vitamin D, and B vitamins to support overall health.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dyskeratosis Congenita Autosomal Recessive 6 C4225356?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dyskeratosis Congenita Autosomal Recessive 6 C4225356. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy